公开(公告)号：US20090023693A1

公开(公告)日：2009-01-22

申请号：US12098831

申请日：2008-04-07

申请人： Vladimir HANES ,  Hartnut Blode ,  Rolf Schurmann ,  Bernd Dusterberg ,  Joachim Marr

发明人： Vladimir HANES ,  Hartnut Blode ,  Rolf Schurmann ,  Bernd Dusterberg ,  Joachim Marr

IPC分类号： A61K31/56 ,  A61P15/18

CPC分类号： A61K31/565 ,  A61K31/585

摘要： The present invention relates to a pharmaceutical combination product with at least 21 daily consecutive dosage units containing from 2.0 mg to 3.0 mg of drospirenone and 1.0 to 2.0 mg of 17β-estradiol in each daily dosage unit followed by intermittent daily dosage units containing the same or smaller amount of drospirenone (i.e. 0.5 mg to 3.0 mg) as the consecutive daily dosage units wherein each intermittent daily dosage unit is preceded by at least one day without administration of drospirenone.These pharmaceutical combination products can be used for female oral contraception, guarantee a withdrawal bleeding each 4 weeks and allow for the full maintenance of the drospirenone related benefits.

摘要翻译： 本发明涉及药物组合产品，其具有至少21个每日连续剂量单位，每个日剂量单位含有2.0mg至3.0mg的屈螺酮和1.0至2.0mg的17β-雌二醇，随后是含有其的间歇性日剂量单位或 较小量的屈螺酮（即0.5mg至3.0mg）作为连续的每日剂量单位，其中每个间歇日剂量单位之前至少一天，而不服用屈螺酮。 这些药物组合产品可用于女性口服避孕药，保证每4周戒断出血，并能充分维持屈螺酮相关益处。